Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Maeyama JI, Iho S, Suzuki F, Hayashi D, Yamamoto T, et al.
…is involves taking advantage of Bacillus Calmette-Guérin's (BCG) superior effects on childhood tuberculosis. Accordingly, here we aimed to develop a booster vaccine for adults who received the BCG vaccine during early childhood. Therefore, we first devised a system to assess the …
Nadhila Idris, Muhammad Nasrum Massi, Rizalinda Sjahril, Ahyar Ahmad, Mochammad M Hatta, et al.
…h despite the availability of Bacille Calmette-Guérin (BCG) vaccination. The limited efficacy of BCG in adults and the low sensitivity of conventional diagnostic methods highlight the urgent need for novel antigens to improve TB immunodiagnostics. **METHODS:** This study co…
Ratih Pujilestari, Andriansjah Rukmana, Anis Karuniawati, M Usman, S Ismail, et al.
… Mycobacterium tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) is the only licensed vaccine against TB, and it is effective in children but not in adults. The Vaccine Research Team, Department of Microbiology FKUI has developed a DNA-based TB vaccine candidate pcDNA3.1-rpfB. Th…
Ko A, Wui SR, Ryu JI, Lee YJ, Hien DTT, et al.
…d by Mycobacterium tuberculosis . Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can o…
Sara Tengattini, Teodora Bavaro, Francesca Rinaldi, Caterina Temporini, Loredano Pollegioni, et al.
…erged. Immunization with the bacillus Calmette-Guérin (BCG) vaccine is one of the primary strategies to mitigate the risk of TB. Despite its widespread use, the current BCG vaccine has limited efficacy, particularly in adults. This review focuses on the rational design of va…
Dellagostin OA, Borsuk S, Oliveira TL, Seixas FK
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG va…
Paloma Rezende Corrêa, Marcos Gustavo Araujo Schwarz, Meydson Benjamim Carvalho Corrêa, Márcia Berrêdo-Pinho, Leila Mendonça-Lima
**BACKGROUND:** The Bacille Calmette-Guérin (BCG) vaccine, developed in the early 20th century, remains the only widely approved prophylactic against tuberculosis (TB). It was derived from an attenuated strain of Mycobacterium bovis. Its protective efficacy against pulmonary…
Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, et al.
…sis Relevant immune targets of the partially efficacious TB vaccine bacille Calmette-Guérin (BCG) remain poorly defined. Mucosal-associated invariant T (MAIT) cells are MHC-related protein 1 (MR1)-restricted T cells, which are reactive against M. tuberculosis , and underexplored …
Jauro S, Larson EC, Gleim JL, Wahlberg BM, Rodgers MA, et al.
…tcomes in people living with HIV. Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, is effective in infants, but its efficacy in adolescents and adults is limited. In this study, we investigated the immune responses elicited by BCG administered via i.v. or intradermal…
Yu J, Fan X, Luan X, Wang R, Cao B, et al.
…seriously affects human health. Until now, the only anti-TB vaccine approved for use is the live attenuated Mycobacterium bovis (M. bovis) vaccine - BCG vaccine, but its protective efficacy is relatively low and does not provide satisfactory protection against TB in adults. There…
Ahmed A, Rakshit S, Adiga V, Dias M, Dwarkanath P, et al.
BCG turns 100 this year and while it might not be the perfect vaccine, it has certainly contributed significantly towards eradication and prevention of spread of tuberculosis (TB). The search for newer and better vaccines for TB is an ongoing endeavor and latest results from tria…
Valencia-Hernandez AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, Pedroza-Roldan C, et al.
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). While BCG protects against TB in children, its protection against pulmonary TB in adults is suboptimal, and the development of a better TB vaccine is a global health priority. Previously, w…
Solomon Jauro, Erica C. Larson, Janelle L. Gleim, Brendon M. Wahlberg, Mark A. Rodgers, et al.
…in people living with HIV (PLWH). Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, is effective in infants, but its efficacy in adolescents and adults is limited. Here, we investigated the immune responses elicited by BCG administered via intravenous (IV) or intrader…
Méndez-Samperio P
…ous disease worldwide. Currently, Bacillus Calmette-Guérin (BCG) remains the only TB vaccine licensed for human use. This TB vaccine is effective in protecting children against severe military TB but offers variable protective efficacy in adults. Therefore, new vaccines against T…
S.H. Choi, Jiyun Park, Jung Joo Hong, Sung Jae Shin, Ju Mi Lee
The Bacillus Calmette-Guérin (BCG) vaccine, the only licensed vaccine against tuberculosis (TB), has played a crucial role in mitigating severe manifestations of the disease, particularly in children. However, its effectiveness against pulmonary TB in adults remains variable, lar…
Melkie ST, Arias L, Farroni C, Jankovic Makek M, Goletti D, et al.
…incomplete protection conferred by bacille Calmette-Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggestin…
GSK Clinical Trials
…s who are PPD-positive either via previous vaccination with BCG and/or conversion to PPD positivity through exposure to Mycobacterium tuberculosis. The BCG vaccine has been widely available for several decades. It is easy and cheap to produce, and when given to neonates or young…
Zhuang L, Ye Z, Li L, Yang L, Gong W
…cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette-Guérin (BCG). However, BCG demonstrates limited efficacy, particularly in adults. Efforts to develop effective TB vaccines have been ongoing for nearly a century. In this re…
Peter Kim, Soumya Swaminathan
…ew drugs in the clinical development pipeline, multiple new vaccine candidates, an array of new diagnostics and multiple clinical trials characterizing the efficacy and effectiveness of these new tools. For chemoprophylaxis and treatment, several new regimens have proven successf…
Wang Y, Sun Y, Zheng Y, Yang Y, He L, et al.
…uses of human death in the world. Bacillus Calmette-Guérin (BCG) provides limited protection in adolescents and adults. To explore the factors reducing efficacy of BCG vaccine, we assess the impacts of interleukin (IL)-10 and alarmins S100A8/A9 on T-cell memory. We found that BCG…
James M. Trauer, Andrew Kawai, Anna K. Coussens, Manjula Datta, Bridget M Williams, et al.
Abstract Background The variable efficacy observed in studies of BCG vaccination is incompletely explained by currently accepted hypotheses, such as latitudinal gradient in non-tuberculous mycobacteria exposure. We investigated heterogeneity in BCG vaccination in the context of p…
Sihang Dong, Shuang Wu, Ke Liang, Hui Zhang, Fangzheng Guo, et al.
…URPOSE:** The only World Health Organization (WHO)-approved vaccine for tuberculosis (TB), Bacillus Calmette-Guérin (BCG), shows limited efficacy, particularly against adult pulmonary TB. Moreover, traditional subunit vaccines often suffer from poor immunogenicity. To addres…
Bhaskar A, Pahuja I, Negi K, Verma A, Ghoshal A, et al.
Bacille Calmette-Guerin (BCG) generates limited long-lasting adaptive memory responses leading to short-lived protection against adult pulmonary tuberculosis (TB). Here, we show that host sirtuin 2 (SIRT2) inhibition by AGK2 significantly enhances the BCG vaccine efficacy during …
Dereck Tait, MD
…is clinical trial will evaluate safety, immunogenicity, and efficacy (prevention of Mtb infection as measured by IGRA conversions) of H56:IC31 in remotely BCG vaccinated adolescents. This clinical trial will evaluate safety, immunogenicity, and prevention of Mtb infection, (meas…
Mustafa AD, Kalyanasundram J, Sabidi S, Song AA, Abdullah M, et al.
…ng prevented and controlled by the Bacille Calmette Guérin (BCG) vaccine, the protective efficacy is highly variable and substandard (0-80%) in adults. Therefore, novel and effective tuberculosis vaccine that can overcome the limitations from BCG vaccine need to be developed. Res…